Irinotecan–temozolomide With Temsirolimus or Dinutuximab in Children With Refractory or Relapsed Neuroblastoma (COG ANBL1221): An Open-Label, Randomised, Phase 2 Trial
The Lancet Oncology - United Kingdom
doi 10.1016/s1470-2045(17)30355-8
Full Text
Open PDFAbstract
Available in full text
Categories
Date
July 1, 2017
Authors
Publisher
Elsevier BV